Search Results - "PREBET, THOMAS"

Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure by PREBET, Thomas, GORE, Steven D, QUESNEL, Bruno, BEACH, C. L, FENAUX, Pierre, VEY, Norbert, ESTERNI, Benjamin, GARDIN, Claude, ITZYKSON, Raphael, THEPOT, Sylvain, DREYFUS, François, RAUZY, Odile Beyne, RECHER, Christian, ADES, Lionel

“…Azacitidine (AZA) is the current standard of care for high-risk (ie, International Prognostic Scoring System high or intermediate 2) myelodysplastic syndrome…”
Get full text

Protective mitochondrial transfer from bone marrow stromal cells to acute myeloid leukemic cells during chemotherapy by Moschoi, Ruxanda, Imbert, Véronique, Nebout, Marielle, Chiche, Johanna, Mary, Didier, Prebet, Thomas, Saland, Estelle, Castellano, Rémy, Pouyet, Laurent, Collette, Yves, Vey, Norbert, Chabannon, Christian, Recher, Christian, Sarry, Jean-Emmanuel, Alcor, Damien, Peyron, Jean-François, Griessinger, Emmanuel

“…Here we demonstrate that in a niche-like coculture system, cells from both primary and cultured acute myeloid leukemia (AML) sources take up functional…”
Get full text

A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission by Vey, Norbert, Bourhis, Jean-Henri, Boissel, Nicolas, Bordessoule, Dominique, Prebet, Thomas, Charbonnier, Aude, Etienne, Anne, Andre, Pascale, Romagne, François, Benson, Don, Dombret, Herve, Olive, Daniel

“…IPH2101 is an anti-killer inhibitory receptor (anti-KIR) mAb that can block KIR-mediated inhibition of natural killer (NK) cells to enhance cytotoxicity…”
Get full text

Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3 -internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation by Bazarbachi, Ali, Bug, Gesine, Baron, Frederic, Brissot, Eolia, Ciceri, Fabio, Dalle, Iman Abou, Döhner, Hartmut, Esteve, Jordi, Floisand, Yngvar, Giebel, Sebastian, Gilleece, Maria, Gorin, Norbert-Claude, Jabbour, Elias, Aljurf, Mahmoud, Kantarjian, Hagop, Kharfan-Dabaja, Mohamed, Labopin, Myriam, Lanza, Francesco, Malard, Florent, Peric, Zinaida, Prebet, Thomas, Ravandi, Farhad, Ruggeri, Annalisa, Sanz, Jaime, Schmid, Christoph, Shouval, Roni, Spyridonidis, Alexandros, Versluis, Jurjen, Vey, Norbert, Savani, Bipin N, Nagler, Arnon, Mohty, Mohamad

“…The ( ) gene is mutated in 25-30% of patients with acute myeloid leukemia (AML). Because of the poor prognosis associated with -internal tandem duplication…”
Get full text

Epigenetics in Cancer: A Hematological Perspective by Stahl, Maximilian, Kohrman, Nathan, Gore, Steven D, Kim, Tae Kon, Zeidan, Amer M, Prebet, Thomas

“…For several decades, we have known that epigenetic regulation is disrupted in cancer. Recently, an increasing body of data suggests epigenetics might be an…”
Get full text

Emerging treatment options for patients with high-risk myelodysplastic syndrome by Bewersdorf, Jan Philipp, Carraway, Hetty, Prebet, Thomas

“…Myelodysplastic syndromes (MDS) are clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis with peripheral blood cytopenias,…”
Get full text

Efficacy and safety of CPX-351 versus 7 + 3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk/secondary AML: post hoc analysis of a randomized, phase 3 trial by Cortes, Jorge E, Lin, Tara L, Asubonteng, Kobby, Faderl, Stefan, Lancet, Jeffrey E, Prebet, Thomas

“…CPX-351 (Europe: Vyxeos liposomal; United States: Vyxeos ) is a dual-drug liposomal encapsulation of daunorubicin and cytarabine in a synergistic 1:5 molar…”
Get full text

Vorinostat in acute myeloid leukemia and myelodysplastic syndromes by Prebet, Thomas, Vey, Norbert

“…the results of conventional treatment for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) remain poor and innovative strategies are warranted…”
Get more information

Acute Myeloid Leukemia With Translocation (8;21) or Inversion (16) in Elderly Patients Treated With Conventional Chemotherapy: A Collaborative Study of the French CBF-AML Intergroup by PREBET, Thomas, BOISSEL, Nicolas, UGO, Valérie, TERRE, Christine, RECHER, Christian, TAVERNIER, Emmanuelle, HUNAULT, Mathilde, ESTERNI, Benjamin, CASTAIGNE, Sylvie, GUILHOT, François, DOMBRET, Hervé, VEY, Norbert, REUTENAUER, Sarah, THOMAS, Xavier, DELAUNAY, Jacques, CAHN, Jean-Yves, PIGNEUX, Arnaud, QUESNEL, Bruno, WITZ, Francis, THEPOT, Sylvain

“…Acute myeloid leukemia (AML) with translocation (t) (8;21) or inversion (inv) (16) is associated with a favorable prognosis when treated with intensive…”
Get full text

Predicting outcome of patients with myelodysplastic syndromes after failure of azacitidine: validation of the North American MDS consortium scoring system by Prebet, Thomas, Fenaux, Pierre, Vey, Norbert

Get full text

Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory Activities by Le Roy, Aude, Prébet, Thomas, Castellano, Rémy, Goubard, Armelle, Riccardi, Florence, Fauriat, Cyril, Granjeaud, Samuel, Benyamine, Audrey, Castanier, Céline, Orlanducci, Florence, Ben Amara, Amira, Pont, Frédéric, Fournié, Jean-Jacques, Collette, Yves, Mege, Jean-Louis, Vey, Norbert, Olive, Daniel

“…Immunomodulatory drugs (IMiDs) are anticancer drugs with immunomodulatory, anti-angiogenesis, anti-proliferative, and pro-apoptotic properties. IMiDs are…”
Get full text

NPM1 mutation is not associated with prolonged complete remission in acute myeloid leukemia patients treated with hypomethylating agents by Prata, Pedro Henrique, Bally, Cécile, Prebet, Thomas, Recher, Christian, Venton, Geoffroy, Thomas, Xavier, Raffoux, Emmanuel, Pigneux, Arnaud, Cluzeau, Thomas, Desoutter, Judith, Gay, Julie, Preudhomme, Claude, Fenaux, Pierre, Adès, Lionel

Get full text

Survival outcomes with oral azacitidine maintenance in patients with acute myeloid leukemia in remission by receipt of initial chemotherapy: subgroup analyses from the phase III QUAZAR AML-001 trial by Wei, Andrew H, Roboz, Gail J, Dombret, Herve, Dohner, Hartmut, Schuh, Andre C, Montesinos, Pau, Selleslag, Dominik, Bondarenko, Sergey N, Prebet, Thomas, Lai, Yinzhi, Skikne, Barry, Beach, C L, Ravandi, Farhad

Get full text

Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure by Ball, Brian J., Famulare, Christopher A., Stein, Eytan M., Tallman, Martin S., Derkach, Andriy, Roshal, Mikhail, Gill, Saar I., Manning, Benjamin M., Koprivnikar, Jamie, McCloskey, James, Testi, Rebecca, Prebet, Thomas, Al Ali, Najla H., Padron, Eric, Sallman, David A., Komrokji, Rami S., Goldberg, Aaron D.

“…•Treatment-naive and relapsed/refractory MDS patients receiving venetoclax and HMAs have an ORR of 59% with 63% of responders proceeding to…”
Get full text

Overexpression of the Promigratory and Prometastatic PTK7 Receptor Is Associated with an Adverse Clinical Outcome in Colorectal Cancer by Lhoumeau, Anne-Catherine, Martinez, Sébastien, Boher, Jean-Marie, Monges, Geneviève, Castellano, Rémy, Goubard, Armelle, Doremus, Marie, Poizat, Flora, Lelong, Bernard, de Chaisemartin, Cécile, Bardin, Florence, Viens, Patrice, Raoul, Jean-Luc, Prebet, Thomas, Aurrand-Lions, Michel, Borg, Jean-Paul, Gonçalves, Anthony

“…Biomarkers and novel therapeutic targets are urgently needed in colorectal cancer (CRC). The pseudo tyrosine kinase receptor 7 (PTK7) is involved in planar…”
Get full text

The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort by Stahl, Maximilian, DeVeaux, Michelle, de Witte, Theo, Neukirchen, Judith, Sekeres, Mikkael A., Brunner, Andrew M., Roboz, Gail J., Steensma, David P., Bhatt, Vijaya R., Platzbecker, Uwe, Cluzeau, Thomas, Prata, Pedro H., Itzykson, Raphaël, Fenaux, Pierre, Fathi, Amir T., Smith, Alexandra, Germing, Ulrich, Ritchie, Ellen K., Verma, Vivek, Nazha, Aziz, Maciejewski, Jaroslaw P., Podoltsev, Nikolai A., Prebet, Thomas, Santini, Valeria, Gore, Steven D., Komrokji, Rami S., Zeidan, Amer M.

“…Most studies of immunosuppressive therapy (IST) in myelodysplastic syndromes (MDS) are limited by small numbers and their single-center nature, and report…”
Get full text

Comprehensive Clinicopathologic and Molecular Analysis of Mast Cell Leukemia With Associated Hematologic Neoplasm: A Report and In-Depth Study of 5 Cases by Li, Philippa, Biancon, Giulia, Patel, Timil, Pan, Zenggang, Kothari, Shalin, Halene, Stephanie, Prebet, Thomas, Xu, Mina L

“…Mast cell leukemia with associated hematologic neoplasm (MCL-AHN) is a rare and highly aggressive entity that remains understudied due to the paucity of cases…”
Get full text

Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort by Stahl, Maximilian, DeVeaux, Michelle, Montesinos, Pau, Itzykson, Raphael, Ritchie, Ellen K., Sekeres, Mikkael A., Barnard, John D., Podoltsev, Nikolai A., Brunner, Andrew M., Komrokji, Rami S., Bhatt, Vijaya R., Al-Kali, Aref, Cluzeau, Thomas, Santini, Valeria, Fathi, Amir T., Roboz, Gail J., Fenaux, Pierre, Litzow, Mark R., Perreault, Sarah, Kim, Tae Kon, Prebet, Thomas, Vey, Norbert, Verma, Vivek, Germing, Ulrich, Bergua, Juan Miguel, Serrano, Josefina, Gore, Steven D., Zeidan, Amer M.

“…Although hypomethylating agents (HMAs) are frequently used in the frontline treatment of older acute myeloid leukemia (AML) patients, little is known about…”
Get full text

Outcome of acute myeloid leukaemia following myelodysplastic syndrome after azacitidine treatment failure by Prébet, Thomas, Gore, Steven D., Thépot, Sylvain, Esterni, Benjamin, Quesnel, Bruno, Beyne Rauzy, Odile, Dreyfus, François, Gardin, Claude, Fenaux, Pierre, Vey, Norbert

Get full text

Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup by Hospital, Marie-Anne, Prebet, Thomas, Bertoli, Sarah, Thomas, Xavier, Tavernier, Emmanuelle, Braun, Thorsten, Pautas, Cécile, Perrot, Aurore, Lioure, Bruno, Rousselot, Philippe, Tamburini, Jérôme, Cluzeau, Thomas, Konopacki, Johanna, Randriamalala, Edouard, Berthon, Céline, Gourin, Marie-Pierre, Recher, Christian, Cahn, Jean-Yves, Ifrah, Norbert, Dombret, Hervé, Boissel, Nicolas

“…Although core-binding factor-acute myeloid leukemia (CBF-AML) (t[8;21] or inv[16]/t[16;16]) represents a favorable cytogenetic AML subgroup, 30% to 40% of…”
Get full text